Prevalence of Growth Hormone Deficiency a Retrospective Single Centre Study
Khalid Aljabri, S.*, M.D., F.R.C.P.C., F.A.C.P. & Samia Bokhari, A., M.D., S.B.E.M.
Department of Endocrinology, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia
Dr. Khalid Aljabri, S., Department of Endocrinology, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Keywords: Growth Hormone Deficiency; Saudi Arabia
Background and Objective
Growth hormone deficiency (GHD) is one of the most important endocrine and treatable causes of short stature. Therefore, the objective of this report is to assess retrospectively the prevalence of GHD in a cohort of Saudi population.
Retrospectively, a total of 47 patients were included for analysis from January 2015 to December 2018 at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia. There were 39 males (83.0%) and 8 females (17.0%). For insulin-like growth factor (IGF-1) and Insulin-like Growth Factorbinding Protein-3 (IGFBP-3), laboratory reference ranges were based on age and sex. This reference range was used to categorize patients as either ‘‘IGF-1 Deficient’’ or ‘‘IGF-1 Normal. The insulin tolerance test (ITT) provocative tests was used for diagnosing GHD. The ITT was performed after an initial baseline blood draw. Regular insulin at a dose of 0.1 unit per body weight (Kg), was administered intravenously, and blood draws occurred at 0 (baseline), 30, 60, 90, and 120 minutes for GH.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).